Via colinérgica anti-inflamatória: um alvo terapêutico no curso da mucosite intestinal induzida experimentalmente por 5-fluorouracil

Detalhes bibliográficos
Autor(a) principal: Mendes, Tiago Santos
Data de Publicação: 2019
Tipo de documento: Tese
Idioma: por
Título da fonte: Repositório Institucional da Universidade Federal do Ceará (UFC)
Texto Completo: http://www.repositorio.ufc.br/handle/riufc/40613
Resumo: The interrelation between the enteric nervous system and the inflammatory process in the pathogenesis of morphofunctional changes caused by 5-Fluorouracil (5-FU) was analyzed. Male Swiss mice weighing 25-30g from the Federal Center of Ceará under protocol 74/2014 received a single dose of 5-FU (450mg / kg-ip) and were treated with neostigmine (NEO-80μg (kg -1), or pyridostigmine (PIRO-2mg / kg-ip) for 3 days starting 1 day before induction with 5-FU were divided into 6 groups: saline control (S), intestinal mucositis (5FU), saline + pyridostigmine (P), saline + neostigmine (N), 5FU + P and 5FU + N. The cervical displacement sacrifice followed 3 days (3d) and 15 days (15d) after administration (inflammatory and postinflammatory phases, respectively), 1cm of the ileal segment was obtained for histopathological and morphometric analysis, myeloperoxidase (MPO), glutathione GSH), malondialdehyde (MDA), IL-1β dosage, acetylcholinesterase activity (AChE), immunohistochemistry for M3 receptors, immunofluorescence for Hu C / D-ChAT, functional parameters of gastric emptying (EG), intestinal transit of the contractile parameters by electrostimulation with voltage curve (10 to 80v) and frequency curve (1 to 32Hz). For statistical analysis it was considered p <0.05, where data were expressed as median for histopathological and morphometric analyzes and mean ± standard error of the mean. In the results of Histopathology we observed the following: (S: 0 (0-1); 5FU 3d: 2 (2-3) *; P: 0 (0-1); N: 0 (0-1); 5FU + P (2-1), 5FU + N: 1 (1-2), 5FU 15d: 1 (0-1), 5FU + P: 1 (0-1), 5FU + N: 1 (0-1). In MPO (S: 3.24 ± 0.31, 5FU: 17.92 ± 2.01 *, P: 3.37 ± 0.69, N: 4.18 ± 0.18, 5FU + P: 16 , 48 ± 3.06 *, 5FU + N: 4.98 ± 0.93 # UMPO / mg tissue), showed difference by increased enzymatic activity in the 5-FU group compared to the S group. (S: 179.88 ± 15.5; 5FU: 648.4 ± 51.6 *; N: 45.38 ± 9.3; 5FU + N: 201.18 ± 28.3 * nM / μg protein / min). In the results of GSH (S: 199.9 ± 8.71, 5FU: 120.9 ± 6.77, P: 107.5 ± 9.38, N: 203.1 ± 4.9, 5FU 376.4 ± 70.98, P: 593.5 ± 100.9, N: 597.385 ± 97.3, FU+P: 297.5 ± 80.58, 5FU+N: 839.43 ± 100.93 5FU+N: 118.8 ± 7.93# NP-GSH μg), the results of AChE activity (S: 971.3 ± 210.9; 5FU: 376,4 ± 70,98; P: 593,5 ± 100,9; N: 597,385 ± 97,3; FU+P: 297,5 ± 80,58; 5FU+N: 839,43 ± 100,93# nM/µg de proteína/min.). In the MDA results, we obtained: (S: 12.5 ± 1.31; 5FU: 29.12 ± 2.8*; P: 11, 3 ± 1.69; N: 13.48 ± 0.18, 5FU+P: 11.48 ± 0.06%; 5FU + N: 11.58 ± 1.43# nMol/g tissue). In the results of the immunohistochemistry M3: (S: 41.87 ± 6.41; 5FU 3d: 78.93 ± 4.57*; 5FU 15d: 76.24 ± 5.53* M3 receptor / mm²) and immunofluorescence in neurons immunoreactive myenteric plexus for HU C/D and cholinergic immunoreactive neurons for ChAT we found a significant relation in the 5FU group: (S: 66.6 ± 2.1; 5FU 3d: 80.3 ± 3.7*%). In contractility, hypercontractility was observed in the ileum of the animals of the 5FU group, tested with electrostimulation and pharmacologically with Acetylcholine and carbachol. On the 15th day after treatment with 5-FU the alterations found in the inflammatory analyzes were reestablished. However, a significant delay in gastric emptying and gastrointestinal transit remains. We can suggest from these results that the alterations in gastrointestinal motility observed by this study and described in the literature are by a decrease in AChE activity in the inflammatory and persistent period in the postinflammatory period, with that the cholinergic anti-inflammatory pathway has potential for therapeutic target without significant changes in inflammatory parameters.
id UFC-7_fd0a7e1622fc03642d5cc44471ecd50a
oai_identifier_str oai:repositorio.ufc.br:riufc/40613
network_acronym_str UFC-7
network_name_str Repositório Institucional da Universidade Federal do Ceará (UFC)
repository_id_str
spelling Via colinérgica anti-inflamatória: um alvo terapêutico no curso da mucosite intestinal induzida experimentalmente por 5-fluorouracilMucosa IntestinalAcetilcolinesteraseFluoruracilaThe interrelation between the enteric nervous system and the inflammatory process in the pathogenesis of morphofunctional changes caused by 5-Fluorouracil (5-FU) was analyzed. Male Swiss mice weighing 25-30g from the Federal Center of Ceará under protocol 74/2014 received a single dose of 5-FU (450mg / kg-ip) and were treated with neostigmine (NEO-80μg (kg -1), or pyridostigmine (PIRO-2mg / kg-ip) for 3 days starting 1 day before induction with 5-FU were divided into 6 groups: saline control (S), intestinal mucositis (5FU), saline + pyridostigmine (P), saline + neostigmine (N), 5FU + P and 5FU + N. The cervical displacement sacrifice followed 3 days (3d) and 15 days (15d) after administration (inflammatory and postinflammatory phases, respectively), 1cm of the ileal segment was obtained for histopathological and morphometric analysis, myeloperoxidase (MPO), glutathione GSH), malondialdehyde (MDA), IL-1β dosage, acetylcholinesterase activity (AChE), immunohistochemistry for M3 receptors, immunofluorescence for Hu C / D-ChAT, functional parameters of gastric emptying (EG), intestinal transit of the contractile parameters by electrostimulation with voltage curve (10 to 80v) and frequency curve (1 to 32Hz). For statistical analysis it was considered p <0.05, where data were expressed as median for histopathological and morphometric analyzes and mean ± standard error of the mean. In the results of Histopathology we observed the following: (S: 0 (0-1); 5FU 3d: 2 (2-3) *; P: 0 (0-1); N: 0 (0-1); 5FU + P (2-1), 5FU + N: 1 (1-2), 5FU 15d: 1 (0-1), 5FU + P: 1 (0-1), 5FU + N: 1 (0-1). In MPO (S: 3.24 ± 0.31, 5FU: 17.92 ± 2.01 *, P: 3.37 ± 0.69, N: 4.18 ± 0.18, 5FU + P: 16 , 48 ± 3.06 *, 5FU + N: 4.98 ± 0.93 # UMPO / mg tissue), showed difference by increased enzymatic activity in the 5-FU group compared to the S group. (S: 179.88 ± 15.5; 5FU: 648.4 ± 51.6 *; N: 45.38 ± 9.3; 5FU + N: 201.18 ± 28.3 * nM / μg protein / min). In the results of GSH (S: 199.9 ± 8.71, 5FU: 120.9 ± 6.77, P: 107.5 ± 9.38, N: 203.1 ± 4.9, 5FU 376.4 ± 70.98, P: 593.5 ± 100.9, N: 597.385 ± 97.3, FU+P: 297.5 ± 80.58, 5FU+N: 839.43 ± 100.93 5FU+N: 118.8 ± 7.93# NP-GSH μg), the results of AChE activity (S: 971.3 ± 210.9; 5FU: 376,4 ± 70,98; P: 593,5 ± 100,9; N: 597,385 ± 97,3; FU+P: 297,5 ± 80,58; 5FU+N: 839,43 ± 100,93# nM/µg de proteína/min.). In the MDA results, we obtained: (S: 12.5 ± 1.31; 5FU: 29.12 ± 2.8*; P: 11, 3 ± 1.69; N: 13.48 ± 0.18, 5FU+P: 11.48 ± 0.06%; 5FU + N: 11.58 ± 1.43# nMol/g tissue). In the results of the immunohistochemistry M3: (S: 41.87 ± 6.41; 5FU 3d: 78.93 ± 4.57*; 5FU 15d: 76.24 ± 5.53* M3 receptor / mm²) and immunofluorescence in neurons immunoreactive myenteric plexus for HU C/D and cholinergic immunoreactive neurons for ChAT we found a significant relation in the 5FU group: (S: 66.6 ± 2.1; 5FU 3d: 80.3 ± 3.7*%). In contractility, hypercontractility was observed in the ileum of the animals of the 5FU group, tested with electrostimulation and pharmacologically with Acetylcholine and carbachol. On the 15th day after treatment with 5-FU the alterations found in the inflammatory analyzes were reestablished. However, a significant delay in gastric emptying and gastrointestinal transit remains. We can suggest from these results that the alterations in gastrointestinal motility observed by this study and described in the literature are by a decrease in AChE activity in the inflammatory and persistent period in the postinflammatory period, with that the cholinergic anti-inflammatory pathway has potential for therapeutic target without significant changes in inflammatory parameters.Analisou-se a via colinérgica anti-inflamatória no processo inflamatório na patogênese das alterações morfofuncionais causadas por 5-Fluorouracil (5-FU). Utilizou camundongos machos Swiss pesando de 25-30g, vindos do biotério central da universidade Federal do Ceará, sob o protocolo 74/2014, receberam dose única de 5-FU (450mg/kg-i.p.) e foram tratados com neostigmina (NEO-80µg/kg-i.p.) ou piridostigmina (PIRO-2mg/kg-i.p.), durante 3 dias iniciando 1 dia antes da indução com 5-FU, foram divididos em 6 grupos: controle salina (S), mucosite intestinal (5FU), salina + piridostigmina (P), salina + neostigmina (N), 5FU+P e 5FU+N. O sacrifício por deslocamento cervical seguiu 3 dias (3d) e 15 dias (15d) após a administração (fase inflamatória e pós inflamatória, respectivamente) foi obtido 1cm do segmento ileal para analise histopatológica e morfometrica, avaliação da mieloperoxidase (MPO), glutationa (GSH), malondialdeido (MDA), dosagem de IL-1β, atividade da acetilcolinesterase (AChE), imunohistoquímica para receptores M3, imunofluorescencia para Hu C/D – ChAT, parâmetros funcionais de esvaziamento gástrico (E.G), transito intestinal (T.I) e dos parâmetros contráteis mediante eletroestimulação com curva de voltagem (10 a 80v) e curva de frequência (1 a 32Hz). Para análise estatística foi considerado p<0,05, onde os dados foram expressos por mediana para analises histopatológica e morfometrica e média ± erro padrão da média. Nos resultados da Histopatologia observamos o seguinte: (S: 0 (0-1); 5FU 3d: 2 (2-3)*; P: 0 (0-1); N: 0 (0-1); 5FU+P: 2 (2-3); 5FU+N: 1 (1-2); 5FU 15d: 1 (0-1); 5FU+P: 1 (0-1); 5FU+N: 1 (0-1). Na MPO (S: 3,24 ± 0,31; 5FU: 17,92 ± 2,01*; P: 3,37 ± 0,69; N: 4,18 ± 0,18; 5FU+P: 16,48 ± 3,06*; 5FU+N: 4,98 ± 0,93# UMPO/mg tecido), mostrou diferença por aumento da atividade enzimática no grupo 5-FU em comparação ao grupo S. Nos resultados da IL1β: (S: 179,88 ± 15,5; 5FU: 648,4 ± 51,6*; N: 45,38 ± 9,3; 5FU+N: 201,18 ± 28,3* nM/µg de proteína/min.). Nos resultados do GSH (S: 199,9 ± 8,71; 5FU: 120,9 ± 6,77; P: 107,5 ± 9,38; N: 203,1 ± 4,9; 5FU+P: 124,7 ± 8,35; 5FU+N: 118,8 ± 7,93# NP-GSH µg/100mg de tecido); nos resultados da atividade da AChE (S: 971,3 ± 210,9; 5FU: 376,4 ± 70,98; P: 593,5 ± 100,9; N: 597,385 ± 97,3; FU+P: 297,5 ± 80,58; 5FU+N: 839,43 ± 100,93# nM/µg de proteína/min.), nos resultados do MDA obtivemos: (S: 12,5 ± 1,31; 5FU: 29,12 ± 2,8*; P: 11,3 ± 1,69; N: 13,48 ± 0,18; 5FU+P: 11,48 ± 0,06#; 5FU+N: 11,58 ± 1,43# nMol/g tecido). Nos resultados da imunohistoquímica M3: (S: 41,87 ± 6,41; 5FU 3d: 78,93 ± 4,57*; 5FU 15d: 76,24 ± 5,53* receptor M3/mm²) e na imunofluorescência nos neurônios do plexo mioentérico imunorreativos para HU C/D e neurônios colinérgicos imunorreativos para ChAT encontramos uma relação significante no grupo 5FU: (S: 66,6 ± 2,1; 5FU 3d: 80,3 ± 3,7*%). Na contratilidade foi observado uma hipercontratilidade no íleo dos animais do grupo 5FU testado com eletroestimulação e farmacologicamente com Acetilcolina e carbacol. No 15° dia após o tratamento com 5-FU as alterações encontradas nas análises inflamatórias foram restabelecidas. Porém, um significativo retardo no esvaziamento gástrico e no trânsito gastrintestinal permanece. Podemos sugerir com esses resultados que as alterações na motilidade gastrointestinal constatadas por este estudo e descritas na literatura são por diminuição da atividade da AChE no período inflamatório e persistente no período pós-inflamatório, com isso a via colinérgica anti-inflamatória tem potencial para alvo terapêutico sem alterações significantes dos parâmetros inflamatórios.Soares, Pedro Marcos GomesLima, Ricardo de FreitasMendes, Tiago Santos2019-04-05T13:15:50Z2019-04-05T13:15:50Z2019-03-08info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/doctoralThesisapplication/pdfMENDES, T. S. Via colinérgica anti-inflamatória: um alvo terapêutico no curso da mucosite intestinal induzida experimentalmente por 5-fluorouracil. 2019. 111f. Tese (Doutorado em Ciências Morfofuncionais) - Faculdade de Medicina, Universidade Federal do Ceará, Fortaleza, 2019.http://www.repositorio.ufc.br/handle/riufc/40613porreponame:Repositório Institucional da Universidade Federal do Ceará (UFC)instname:Universidade Federal do Ceará (UFC)instacron:UFCinfo:eu-repo/semantics/openAccess2019-04-05T13:42:25Zoai:repositorio.ufc.br:riufc/40613Repositório InstitucionalPUBhttp://www.repositorio.ufc.br/ri-oai/requestbu@ufc.br || repositorio@ufc.bropendoar:2024-09-11T18:17:48.305125Repositório Institucional da Universidade Federal do Ceará (UFC) - Universidade Federal do Ceará (UFC)false
dc.title.none.fl_str_mv Via colinérgica anti-inflamatória: um alvo terapêutico no curso da mucosite intestinal induzida experimentalmente por 5-fluorouracil
title Via colinérgica anti-inflamatória: um alvo terapêutico no curso da mucosite intestinal induzida experimentalmente por 5-fluorouracil
spellingShingle Via colinérgica anti-inflamatória: um alvo terapêutico no curso da mucosite intestinal induzida experimentalmente por 5-fluorouracil
Mendes, Tiago Santos
Mucosa Intestinal
Acetilcolinesterase
Fluoruracila
title_short Via colinérgica anti-inflamatória: um alvo terapêutico no curso da mucosite intestinal induzida experimentalmente por 5-fluorouracil
title_full Via colinérgica anti-inflamatória: um alvo terapêutico no curso da mucosite intestinal induzida experimentalmente por 5-fluorouracil
title_fullStr Via colinérgica anti-inflamatória: um alvo terapêutico no curso da mucosite intestinal induzida experimentalmente por 5-fluorouracil
title_full_unstemmed Via colinérgica anti-inflamatória: um alvo terapêutico no curso da mucosite intestinal induzida experimentalmente por 5-fluorouracil
title_sort Via colinérgica anti-inflamatória: um alvo terapêutico no curso da mucosite intestinal induzida experimentalmente por 5-fluorouracil
author Mendes, Tiago Santos
author_facet Mendes, Tiago Santos
author_role author
dc.contributor.none.fl_str_mv Soares, Pedro Marcos Gomes
Lima, Ricardo de Freitas
dc.contributor.author.fl_str_mv Mendes, Tiago Santos
dc.subject.por.fl_str_mv Mucosa Intestinal
Acetilcolinesterase
Fluoruracila
topic Mucosa Intestinal
Acetilcolinesterase
Fluoruracila
description The interrelation between the enteric nervous system and the inflammatory process in the pathogenesis of morphofunctional changes caused by 5-Fluorouracil (5-FU) was analyzed. Male Swiss mice weighing 25-30g from the Federal Center of Ceará under protocol 74/2014 received a single dose of 5-FU (450mg / kg-ip) and were treated with neostigmine (NEO-80μg (kg -1), or pyridostigmine (PIRO-2mg / kg-ip) for 3 days starting 1 day before induction with 5-FU were divided into 6 groups: saline control (S), intestinal mucositis (5FU), saline + pyridostigmine (P), saline + neostigmine (N), 5FU + P and 5FU + N. The cervical displacement sacrifice followed 3 days (3d) and 15 days (15d) after administration (inflammatory and postinflammatory phases, respectively), 1cm of the ileal segment was obtained for histopathological and morphometric analysis, myeloperoxidase (MPO), glutathione GSH), malondialdehyde (MDA), IL-1β dosage, acetylcholinesterase activity (AChE), immunohistochemistry for M3 receptors, immunofluorescence for Hu C / D-ChAT, functional parameters of gastric emptying (EG), intestinal transit of the contractile parameters by electrostimulation with voltage curve (10 to 80v) and frequency curve (1 to 32Hz). For statistical analysis it was considered p <0.05, where data were expressed as median for histopathological and morphometric analyzes and mean ± standard error of the mean. In the results of Histopathology we observed the following: (S: 0 (0-1); 5FU 3d: 2 (2-3) *; P: 0 (0-1); N: 0 (0-1); 5FU + P (2-1), 5FU + N: 1 (1-2), 5FU 15d: 1 (0-1), 5FU + P: 1 (0-1), 5FU + N: 1 (0-1). In MPO (S: 3.24 ± 0.31, 5FU: 17.92 ± 2.01 *, P: 3.37 ± 0.69, N: 4.18 ± 0.18, 5FU + P: 16 , 48 ± 3.06 *, 5FU + N: 4.98 ± 0.93 # UMPO / mg tissue), showed difference by increased enzymatic activity in the 5-FU group compared to the S group. (S: 179.88 ± 15.5; 5FU: 648.4 ± 51.6 *; N: 45.38 ± 9.3; 5FU + N: 201.18 ± 28.3 * nM / μg protein / min). In the results of GSH (S: 199.9 ± 8.71, 5FU: 120.9 ± 6.77, P: 107.5 ± 9.38, N: 203.1 ± 4.9, 5FU 376.4 ± 70.98, P: 593.5 ± 100.9, N: 597.385 ± 97.3, FU+P: 297.5 ± 80.58, 5FU+N: 839.43 ± 100.93 5FU+N: 118.8 ± 7.93# NP-GSH μg), the results of AChE activity (S: 971.3 ± 210.9; 5FU: 376,4 ± 70,98; P: 593,5 ± 100,9; N: 597,385 ± 97,3; FU+P: 297,5 ± 80,58; 5FU+N: 839,43 ± 100,93# nM/µg de proteína/min.). In the MDA results, we obtained: (S: 12.5 ± 1.31; 5FU: 29.12 ± 2.8*; P: 11, 3 ± 1.69; N: 13.48 ± 0.18, 5FU+P: 11.48 ± 0.06%; 5FU + N: 11.58 ± 1.43# nMol/g tissue). In the results of the immunohistochemistry M3: (S: 41.87 ± 6.41; 5FU 3d: 78.93 ± 4.57*; 5FU 15d: 76.24 ± 5.53* M3 receptor / mm²) and immunofluorescence in neurons immunoreactive myenteric plexus for HU C/D and cholinergic immunoreactive neurons for ChAT we found a significant relation in the 5FU group: (S: 66.6 ± 2.1; 5FU 3d: 80.3 ± 3.7*%). In contractility, hypercontractility was observed in the ileum of the animals of the 5FU group, tested with electrostimulation and pharmacologically with Acetylcholine and carbachol. On the 15th day after treatment with 5-FU the alterations found in the inflammatory analyzes were reestablished. However, a significant delay in gastric emptying and gastrointestinal transit remains. We can suggest from these results that the alterations in gastrointestinal motility observed by this study and described in the literature are by a decrease in AChE activity in the inflammatory and persistent period in the postinflammatory period, with that the cholinergic anti-inflammatory pathway has potential for therapeutic target without significant changes in inflammatory parameters.
publishDate 2019
dc.date.none.fl_str_mv 2019-04-05T13:15:50Z
2019-04-05T13:15:50Z
2019-03-08
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/doctoralThesis
format doctoralThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv MENDES, T. S. Via colinérgica anti-inflamatória: um alvo terapêutico no curso da mucosite intestinal induzida experimentalmente por 5-fluorouracil. 2019. 111f. Tese (Doutorado em Ciências Morfofuncionais) - Faculdade de Medicina, Universidade Federal do Ceará, Fortaleza, 2019.
http://www.repositorio.ufc.br/handle/riufc/40613
identifier_str_mv MENDES, T. S. Via colinérgica anti-inflamatória: um alvo terapêutico no curso da mucosite intestinal induzida experimentalmente por 5-fluorouracil. 2019. 111f. Tese (Doutorado em Ciências Morfofuncionais) - Faculdade de Medicina, Universidade Federal do Ceará, Fortaleza, 2019.
url http://www.repositorio.ufc.br/handle/riufc/40613
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Institucional da Universidade Federal do Ceará (UFC)
instname:Universidade Federal do Ceará (UFC)
instacron:UFC
instname_str Universidade Federal do Ceará (UFC)
instacron_str UFC
institution UFC
reponame_str Repositório Institucional da Universidade Federal do Ceará (UFC)
collection Repositório Institucional da Universidade Federal do Ceará (UFC)
repository.name.fl_str_mv Repositório Institucional da Universidade Federal do Ceará (UFC) - Universidade Federal do Ceará (UFC)
repository.mail.fl_str_mv bu@ufc.br || repositorio@ufc.br
_version_ 1813028742878986240